- Previous Close
0.680 - Open
0.700 - Bid 0.680 x --
- Ask 0.700 x --
- Day's Range
0.700 - 0.700 - 52 Week Range
0.400 - 0.760 - Volume
64,000 - Avg. Volume
657,540 - Market Cap (intraday)
494.922M - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.020 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Baijin Life Science Holdings Limited, an investment holding company, engages in the purchase, process, design, production, and wholesale distribution of pearls and jewelry products. It operates through Sales of Pearls and Jewellery Products; Strategic Investment and Financial Services; Skincare Solutions; Research and Development Services; and Brand Marketing and Consulting Services segment. The company is also involved in the real estate financial assets investment business. In addition, it offers skincare solutions products under the FO brand name to cosmetics stores and hospitals through sales contracts, as well as individuals through online sales platforms. Further, the company provides scientific and pharmaceutical research and development services; and brand marketing and consulting services. It operates in Hong Kong, the People's Republic of China, the United States, Europe, and Asia. The company was formerly known as Affluent Partners Holdings Limited and changed its name to Baijin Life Science Holdings Limited in January 2025. Baijin Life Science Holdings Limited was incorporated in 2014 and is based in Wan Chai, Hong Kong.
www.baijinlifescience.comRecent News: 1466.HK
View MorePerformance Overview: 1466.HK
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1466.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1466.HK
View MoreValuation Measures
Market Cap
480.78M
Enterprise Value
502.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.68
Price/Book (mrq)
5.71
Enterprise Value/Revenue
5.19
Enterprise Value/EBITDA
1.22k
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.42%
Return on Assets (ttm)
-2.20%
Return on Equity (ttm)
-8.90%
Revenue (ttm)
99.45M
Net Income Avi to Common (ttm)
-11.36M
Diluted EPS (ttm)
-0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
44.96M
Total Debt/Equity (mrq)
61.16%
Levered Free Cash Flow (ttm)
-2.68M